ResMed Inc. (NYSE:RMD) – Stock analysts at William Blair boosted their Q2 2019 EPS estimates for ResMed in a research report issued on Thursday, October 25th. William Blair analyst M. Kaczor now forecasts that the medical equipment provider will post earnings per share of $0.94 for the quarter, up from their previous forecast of $0.91. William Blair also issued estimates for ResMed’s Q3 2019 earnings at $0.94 EPS, Q4 2019 earnings at $1.01 EPS, FY2019 earnings at $3.68 EPS, Q1 2020 earnings at $0.90 EPS, Q2 2020 earnings at $1.02 EPS, Q3 2020 earnings at $1.03 EPS, Q4 2020 earnings at $1.10 EPS and FY2020 earnings at $4.05 EPS.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 25th. The medical equipment provider reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.01. The company had revenue of $588.28 million during the quarter, compared to the consensus estimate of $576.66 million. ResMed had a return on equity of 25.82% and a net margin of 13.94%.

RMD has been the topic of several other reports. Credit Suisse Group raised ResMed from a “neutral” rating to an “outperform” rating in a research note on Friday. BMO Capital Markets upped their price target on ResMed from $107.00 to $109.00 and gave the stock a “market perform” rating in a research note on Friday. Goldman Sachs Group initiated coverage on ResMed in a research note on Sunday, July 1st. They issued a “buy” rating on the stock. Finally, Zacks Investment Research cut ResMed from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $100.67.

Shares of RMD stock opened at $104.10 on Monday. The firm has a market capitalization of $14.85 billion, a P/E ratio of 29.49, a PEG ratio of 2.68 and a beta of 0.87. ResMed has a twelve month low of $81.01 and a twelve month high of $116.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.56 and a current ratio of 2.08.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in shares of ResMed in the second quarter worth $131,000. Qube Research & Technologies Ltd purchased a new stake in shares of ResMed in the second quarter worth $148,000. Piedmont Investment Advisors LLC purchased a new stake in shares of ResMed in the second quarter worth $167,000. Cornerstone Wealth Management LLC purchased a new stake in shares of ResMed in the second quarter worth $167,000. Finally, Cerebellum GP LLC purchased a new stake in shares of ResMed in the third quarter worth $186,000. 63.93% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CFO Brett Sandercock sold 2,000 shares of the company’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $107.45, for a total value of $214,900.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider David Pendarvis sold 2,810 shares of the company’s stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $106.20, for a total value of $298,422.00. Following the completion of the sale, the insider now directly owns 101,893 shares in the company, valued at $10,821,036.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,420 shares of company stock worth $1,468,482. 1.24% of the stock is owned by insiders.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 13th. Investors of record on Thursday, November 8th will be paid a $0.37 dividend. The ex-dividend date is Wednesday, November 7th. This represents a $1.48 annualized dividend and a yield of 1.42%. ResMed’s payout ratio is 41.93%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Article: What is a put option?

Earnings History and Estimates for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.